BridgeMD
Corticosteroid in acute urticaria in emergency department
EU CTIS ID: 2024-515308-38-00
What this study is testing
To demonstrate the non-inferiority of the efficacy of a single antihistamine in comparaison with an association of antihistamine and corticosteroid in the treatment of acute urticaria in emergency departments
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age > 18 years
- Acute urticaria with angioedema without laryngeal edema
- Obtain patient’s consent
- Social security affiliation
You likely can't join if
- Pregnancy or breastfeeding
- Atopic dermatitis
- Eczema
- Bullous pemphigoid
- Acute exanthematous pustulosis
- Diabetes mellitus
See the full eligibility criteria
- Age > 18 years
- Acute urticaria with angioedema without laryngeal edema
- Obtain patient’s consent
- Social security affiliation
- Pregnancy or breastfeeding
- Atopic dermatitis
- Eczema
- Bullous pemphigoid
- Acute exanthematous pustulosis
- Diabetes mellitus
- Gastrointestinal ulcer
- Refusal to participate
- Known allergy to the study drugs or formulation ingredients
- Hypersensitivity to lactose
- Known Renal failure defined by creatinine clearance < 10 mL/min or cardiac failure defined by ejection fraction < 40%
- Acute hives with anaphylaxis
- Hypersensitivity to active substance, to cetirizine, to hydroxyzine and to pipérazine and excipients
- Contre-indication to corticotherapy: o Any live vaccine o Psychotic states still uncontrolled by treatment limiting the participant's compliance with the research o Some viruses in evolution (including hepatitis, herpes, chicken pox, shingles). o Any infectious condition
- Bradykinin angioedema
- Angioedema without urticaria (hives)
- Laryngeal edema with urticaria (hives)
- Corticosteroid administration in the previous 5 days visiting the emergency department
- Antihistamines greater than 1 tablet per day in the previous 5 days visiting the ED
- Other treatment for urticaria : omalizumab, montelukast, ciclosporine A
- Chronic urticaria before acute urticaria diagnosis
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.